Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

Journal of Autoimmunity

Volumn 58, Issue , 2015, Pages 48-58

  Rosenzwajg, Michelle ^a,b,c   Churlaud, Guillaume ^a,b,c   Mallone, Roberto ^a,d,e,f   Six, Adrien ^a,b,c   Dérian, Nicolas ^a,b,c   Chaara, Wahiba ^a,b,c   Lorenzon, Roberta ^a,b,c   Long, S Alice ^g   Buckner, Jane H ^g   Afonso, Georgia ^a,d,e,f   Pham, Hang Phuong ^h   Hartemann, Agnès ^h   Yu, Aixin ^i,j   Pugliese, Alberto ^i,j   Malek, Thomas R ^i,j   Klatzmann, David ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c Unit of Dermatology   (France)

^d INSTITUT COCHIN   (France)

^e CNRS   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g BENAROYA RESEARCH INSTITUTE   (United States)

^h PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

ⁱ UNIVERSITY OF MIAMI   (United States)

^j UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Immunopathology; Immunotherapy; Inflammation; Pharmacokinetics; Tolerance

Indexed keywords

ALDESLEUKIN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMATE DECARBOXYLASE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12P40; INTERLEUKIN 12P70; INTERLEUKIN 13; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 9; MACROPHAGE DERIVED CHEMOKINE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; STAT5 PROTEIN; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; TNFRSF18 PROTEIN, HUMAN;

ABSENCE OF SIDE EFFECTS; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; BLOOD SAMPLING; CELL EXPANSION; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; IC50; IMMUNE RESPONSE; IMMUNOPHENOTYPING; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; MALE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SUBCUTANEOUS IMMUNOTHERAPY; T LYMPHOCYTE ACTIVATION; TH1 TH2 BALANCE; UPREGULATION; ADOLESCENT; CELL CULTURE; DIABETES MELLITUS, TYPE 1; DOSE CALCULATION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIGENS, CD8; CELLS, CULTURED; CYTOKINES; DIABETES MELLITUS, TYPE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DOSAGE CALCULATIONS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; GLUCOCORTICOID-INDUCED TNFR-RELATED PROTEIN; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; INSULIN-SECRETING CELLS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; STAT5 TRANSCRIPTION FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSCRIPTOME; YOUNG ADULT;

EID: 84928589620     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2015.01.001     Document Type: Article

References (68)

1. Sakaguchi S., Miyara M., Costantino C.M., Hafler D.A. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 2010, 10:490-500.
2. Ait-Oufella H., Salomon B.L., Potteaux S., Robertson A.K., Gourdy P., Zoll J., et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat Med 2006, 12:178-180.
3. Campbell D.J., Koch M.A. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011, 11:119-130.
4. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010, 11:7-13.
5. Bacchetta R., Passerini L., Gambineri E., Dai M., Allan S.E., Perroni L., et al. Defective regulatory and effector T cell functions in patients with FOXP3 mutations. JClin Invest 2006, 116:1713-1722.
6. Bennett C.L., Christie J., Ramsdell F., Brunkow M.E., Ferguson P.J., Whitesell L., et al. The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 2001, 27:20-21.
7. Brunkow M.E., Jeffery E.W., Hjerrild K.A., Paeper B., Clark L.B., Yasayko S.A., et al. Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet 2001, 27:68-73.
8. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
9. Brusko T.M., Wasserfall C.H., Clare-Salzler M.J., Schatz D.A., Atkinson M.A. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005, 54:1407-1414.
10. Lindley S., Dayan C.M., Bishop A., Roep B.O., Peakman M., Tree T.I. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 2005, 54:92-99.
11. Long S.A., Cerosaletti K., Bollyky P.L., Tatum M., Shilling H., Zhang S., et al. Defects in IL-2R signaling contribute to diminished maintenance of FOXP3 expression in CD4(+)CD25(+) regulatory T-cells of type 1 diabetic subjects. Diabetes 2010, 59:407-415.
12. Buckner J.H. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat Rev Immunol 2010, 10:849-859.
13. Long S.A., Buckner J.H. CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game. JImmunol 2011, 187:2061-2066.
14. Grinberg-Bleyer Y., Baeyens A., You S., Elhage R., Fourcade G., Gregoire S., et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. JExp Med 2010, 207:1871-1878.
15. Koreth J., Matsuoka K., Kim H.T., McDonough S.M., Bindra B., Alyea E.P., et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. NEngl J Med 2011, 365:2055-2066.
16. Matsuoka K., Koreth J., Kim H.T., Bascug G., McDonough S., Kawano Y., et al. Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med 2013, 5. 179ra43.
17. Saadoun D., Rosenzwajg M., Joly F., Six A., Carrat F., Thibault V., et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. NEngl J Med 2011, 365:2067-2077.
18. Tang Q., Bluestone J.A., Kang S.M. CD4(+)Foxp3(+) regulatory T cell therapy in transplantation. JMol Cell Biol 2012, 4:11-21.
19. Wood K.J., Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003, 3:199-210.
20. Cacoub P., Poynard T., Ghillani P., Charlotte F., Olivi M., Piette J.C., et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC group. Multidepartment virus C. Arthritis Rheum 1999, 42:2204-2212.
21. Dendrou C.A., Plagnol V., Fung E., Yang J.H., Downes K., Cooper J.D., et al. Cell-specific protein phenotypes for the autoimmune locus IL2RA using a genotype-selectable human bioresource. Nat Genet 2009, 41:1011-1015.
22. Qu H.Q., Montpetit A., Ge B., Hudson T.J., Polychronakos C. Toward further mapping of the association between the IL2RA locus and type 1 diabetes. Diabetes 2007, 56:1174-1176.
23. Vella A., Cooper J.D., Lowe C.E., Walker N., Nutland S., Widmer B., et al. Localization of a type 1 diabetes locus in the IL2RA/CD25 region by use of tag single-nucleotide polymorphisms. Am J Hum Genet 2005, 76:773-779.
24. Todd J.A. Etiology of type 1 diabetes. Immunity 2010, 32:457-467.
25. Todd J.A., Walker N.M., Cooper J.D., Smyth D.J., Downes K., Plagnol V., et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007, 39:857-864.
26. Wang W.Y., Barratt B.J., Clayton D.G., Todd J.A. Genome-wide association studies: theoretical and practical concerns. Nat Rev Genet 2005, 6:109-118.
27. Ferraro A., Socci C., Stabilini A., Valle A., Monti P., Piemonti L., et al. Expansion of Th17 cells and functional defects in T regulatory cells are key features of the pancreatic lymph nodes in patients with type 1 diabetes. Diabetes 2011, 60:2903-2913.
28. Bluestone J.A., Herold K., Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010, 464:1293-1300.
29. Battaglia M., Roncarolo M.G. Immune intervention with T regulatory cells: past lessons and future perspectives for type 1 diabetes. Semin Immunol 2011, 23:182-194.
30. Tang Q., Adams J.Y., Penaranda C., Melli K., Piaggio E., Sgouroudis E., et al. Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction. Immunity 2008, 28:687-697.
31. Bougneres P.F., Carel J.C., Castano L., Boitard C., Gardin J.P., Landais P., et al. Factors associated with early remission of type I diabetes in children treated with cyclosporine. NEngl J Med 1988, 318:663-670.
32. Feutren G., Papoz L., Assan R., Vialettes B., Karsenty G., Vexiau P., et al. Cyclosporin increases the rate and length of remissions in insulin-dependent diabetes of recent onset. Results of a multicentre double-blind trial. Lancet 1986, 2:119-124.
33. Stiller C.R., Dupre J., Gent M., Jenner M.R., Keown P.A., Laupacis A., et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984, 223:1362-1367.
34. Skyler J.S. Immune intervention for type 1 diabetes, 2012-2013. Diabetes Technol Ther 2014, 16(Suppl.1):S85-S91.
35. Orban T., Bundy B., Becker D.J., Dimeglio L.A., Gitelman S.E., Goland R., et al. Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment. Diabetes Care 2014, 37:1069-1075.
36. Herold K.C., Gitelman S.E., Ehlers M.R., Gottlieb P.A., Greenbaum C.J., Hagopian W., et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013, 62:3766-3774.
37. Hagopian W., Ferry R.J., Sherry N., Carlin D., Bonvini E., Johnson S., et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled protege trial. Diabetes 2013, 62:3901-3908.
38. Orban T., Beam C.A., Xu P., Moore K., Jiang Q., Deng J., et al. Reduction in CD4 Central memory T-cell subset in co-stimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline. Diabetes 2014, 63:3449-3457.
39. Garg G., Tyler J.R., Yang J.H., Cutler A.J., Downes K., Pekalski M., et al. Type 1 diabetes-associated IL2RA variation lowers IL-2 signaling and contributes to diminished CD4+CD25+ regulatory T cell function. JImmunol 2012, 188:4644-4653.
40. Hartemann A., Bensimon G., Payan C., Jacqueminet S., Bourron O., Nicolas N., et al. Low-dose Interleukin-2 induces regulatory T cells and is well tolerated in patients with type-1 diabetes: results of a phase I/II randomized, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013, 1:295-305.
41. Long S.A., Rieck M., Tatum M., Bollyky P.L., Wu R.P., Muller I., et al. Low-dose antigen promotes induction of FOXP3 in human CD4+ T cells. JImmunol 2011, 187:3511-3520.
42. Martinuzzi E., Afonso G., Gagnerault M.C., Naselli G., Mittag D., Combadiere B., et al. acDCs enhance human antigen-specific T-cell responses. Blood 2011, 118:2128-2137.
43. Scharenberg J.G., Stam A.G., von Blomberg B.M., Roest G.J., Palmer P.A., Franks C.R., et al. The development of anti-interleukin-2 (IL-2) antibodies in cancer patients treated with recombinant IL-2. Eur J Cancer 1994, 30A:1804-1809.
44. Hori T., Uchiyama T., Tsudo M., Umadome H., Ohno H., Fukuhara S., et al. Establishment of an interleukin 2-dependent human T cell line from a patient with T cell chronic lymphocytic leukemia who is not infected with human T cell leukemia/lymphoma virus. Blood 1987, 70:1069-1072.
45. Li S., Rouphael N., Duraisingham S., Romero-Steiner S., Presnell S., Davis C., et al. Molecular signatures of antibody responses derived from a systems biology study of five human vaccines. Nat Immunol 2014, 15:195-204.
46. Mootha V.K., Lindgren C.M., Eriksson K.F., Subramanian A., Sihag S., Lehar J., et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34:267-273.
47. Subramanian A., Tamayo P., Mootha V.K., Mukherjee S., Ebert B.L., Gillette M.A., et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005, 102:15545-15550.
48. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? the example of natural killer cells. Science 2011, 331:44-49.
49. Chaput N., Louafi S., Bardier A., Charlotte F., Vaillant J.C., Menegaux F., et al. Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 2009, 58:520-529.
50. Miyara M., Yoshioka Y., Kitoh A., Shima T., Wing K., Niwa A., et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009, 30:899-911.
51. Gavin M.A., Rasmussen J.P., Fontenot J.D., Vasta V., Manganiello V.C., Beavo J.A., et al. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 2007, 445:771-775.
52. Morgan D.A., Ruscetti F.W., Gallo R. Selective invitro growth of T lymphocytes from normal human bone marrows. Science 1976, 193:1007-1008.
53. Chang A.E., Rosenberg S.A. Overview of interleukin-2 as an immunotherapeutic agent. Semin Surg Oncol 1989, 5:385-390.
54. Giedlin M.A., Zimmerman R.J. The use of recombinant human interleukin-2 in treating infectious diseases. Curr Opin Biotechnol 1993, 4:722-726.
55. Sadlack B., Lohler J., Schorle H., Klebb G., Haber H., Sickel E., et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995, 25:3053-3059.
56. Zorn E., Nelson E.A., Mohseni M., Porcheray F., Kim H., Litsa D., et al. IL-2 regulates FOXP3 expression in human CD4+CD25+ regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells invivo. Blood 2006, 108:1571-1579.
57. Malek T.R., Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 2010, 33:153-165.
58. Ito S., Bollard C.M., Carlsten M., Melenhorst J.J., Biancotto A., Wang E., et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory T cells and natural killer cells in healthy volunteers. Mol Ther 2014, 58:1388-1395.
59. Boyman O., Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol 2012, 12:180-190.
60. Oldenhove G., Bouladoux N., Wohlfert E.A., Hall J.A., Chou D., Dos Santos L., et al. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 2009, 31:772-786.
61. Long S.A., Rieck M., Sanda S., Bollyky J.B., Samuels P.L., Goland R., et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012, 61:2340-2348.
62. Walker J.A., Barlow J.L., McKenzie A.N. Innate lymphoid cells-how did we miss them?. Nat Rev Immunol 2013, 13:75-87.
63. Tran G.T., Hodgkinson S.J., Carter N.M., Verma N.D., Plain K.M., Boyd R., et al. IL-5 promotes induction of antigen-specific CD4+CD25+ T regulatory cells that suppress autoimmunity. Blood 2012, 119:4441-4450.
64. Kennedy-Nasser A.A., Ku S., Castillo-Caro P., Hazrat Y., Wu M.F., Liu H., et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res Off J Am Assoc Cancer Res 2014, 20:2215-2225.
65. Castela E., Le Duff F., Butori C., Ticchioni M., Hofman P., Bahadoran P., et al. Effects of low-dose recombinant interleukin 2 to promote T-regulatory cells in alopecia areata. JAMA Dermatol 2014, 150:748-751.
66. Klatzmann D. Immunoregulation without immunosuppression: the promise of low dose IL-2. FOCIS meeting Chicago 2014.
67. Von Spee-Mayer C.S.E., Rose A., Humrich J., Riemekasten G. Low-dose interleukin-2 therapy caused selective expansion of Tregs together with rapid reduction of disease activity in a patient with severe refractory SLE. EULAR meeting Paris 2014.
68. Yu D. Low-dose interleukin-2 in active systemic lupus erythematosus. FOCIS meeting Chicago 2014.